11:22 EDT Arvinas (ARVN) trading halted, news pending
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas Buy Rating Driven by Robust ARV-102 LRRK2 Degrader Data and Clear Neurodegeneration Development Path
- Balanced View on Arvinas: Early Promise of ARV-102 Offset by Clinical, Safety, and Competitive Uncertainties Supporting a Hold Rating
- Arvinas price target raised to $21 from $18 at Citi
- ARV-102 Data Strengthens Neurodegeneration Pipeline Prospects, Supporting Higher $16 Target and Buy Rating on Arvinas
- Arvinas Reports Positive Phase 1 Data for ARV-102